Aurobindo Pharma Shares Fall After USFDA Reports Major Quality and Data Issues
Shares of Aurobindo Pharma Ltd dropped following a recent inspection by the US Food and Drug Administration (USFDA). The regulator issued nine observations after visiting the company’s Unit 7 manufacturing plant in Jedcherla, Telangana. This facility is a major hub for the company’s US business, producing tablets and capsules that make up nearly 20% of its US product portfolio.
Key Quality and Safety Observations
The USFDA inspection, conducted from January 28 to February 10, revealed serious gaps in quality control and manufacturing standards. According to the report:
- Inadequate Investigations: Quality checks were not thorough enough, and the company failed to identify the root causes of production problems.
- Scientific Justification: Some failed test results were closed without proper scientific evidence, raising concerns about the accuracy of lab findings.
- Manufacturing Oversight: Deviations in the manufacturing process were not properly checked for their impact on medicine quality. Additionally, record-keeping for various batches was inconsistent or incomplete.
- Cleaning and Maintenance: Procedures for cleaning and equipment maintenance lacked supporting data. This suggests a lack of control over daily operations.
Severe Contamination Risks
The USFDA highlighted dangerous levels of residue and contamination in the facility’s airflow systems (HVAC and HEPA). Inspectors found:
- Residue Build-up: Air ducts and filters had years of chemical build-up. Swab tests showed drug residues as high as 545 times the acceptable limit.
- Biological Hazards: Inspectors found bird droppings, layers of dust, and microbial growth (including Pseudomonas and E. coli) inside the air systems.
- Poor Monitoring: The company lacked documented cleaning procedures for these systems, and quality assurance teams failed to physically verify the cleanliness of the production areas.
Data Integrity Concerns
The report also raised “red flags” regarding how the company handles its digital records. Weaknesses in the computer systems could allow for unauthorized changes to data. Specific issues included:
- Shared login credentials among employees.
- Backdating of records and the ability to delete files.
- Unverifiable copies of important data.
These failures often lead to deeper scrutiny from the FDA, higher costs to fix the issues, and potential delays in selling products in the US.
Market Impact and Next Steps
The Jedcherla site supports over 150 product filings (ANDAs) for the US market. The facility has already issued a voluntary recall for certain tablets due to impurities.
While a “Form 483” (the list of observations) is not an immediate ban on production, it is a serious warning. Aurobindo Pharma must now provide a detailed plan to the USFDA explaining how it will fix these problems. If the response is not fast or credible, the company could face a formal Warning Letter or restrictions on importing its products into the United States.
Also Read : Social Media Age Restrictions in India Ashwini Vaishnaw Confirms Talks
